PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 February 1.
Published in final edited form as:
J Acquir Immune Defic Syndr. 2012 February 1; 59(2): 149–154.
doi: 10.1097/QAI.0b013e318240566b

Table 1

Characteristics of 6 clinical groups. Values represent either mean (with standard deviation) for normally distributed continuous variables, median and quartile scores for non-normally distributed continuous variables, and frequency percentages for categorical variables.

Group 1
HIV neg,
HCV RNA
neg
(N = 392)
Group 2
HIV neg,
HCV RNA
pos
(N = 42)
Group 3
HIV+, not
AIDS,
HCV RNA
neg
(N = 480)
Group 4.
HIV+, not
AIDS,
HCV RNA
pos
(N = 96)
Group 5
AIDS,
HCV RNA
neg
N= 241
Group 6
AIDS,
HCV RNA
pos
(N = 88)
P, significant
comparisons
Age36.1 (9.8)45.9 (8.2)38.3 (8.8)47.8 (6.3)43.2 (7.8)48.3 (5.1)1 v 2!!, 3*, 5*, 6*
3 v 6*
5 v 6*
Ethnicity9.4% W
22.7%
Hisp
63.8% AA
4.1% Other
11.9 W
21.4 Hisp
64.3 AA
2.4 Other
9.6 W
16.9 Hisp
70.0 AA
3.5 Other
15.6 W
14.6 Hisp
69.8 AA
0 Other
19.1 W
19.1 Hisp
57.3 AA
4.6 Other
10.2 W
22.7 Hisp
64.8 AA
2.3 Other
χ2= 31.1, 0.008
Education Level1: 30.6%
2: 31.4%
3: 29.6%
4: 8.4%
1: 52.4%
2: 38.1%
3: 9.5%
4: 0%
1: 30.6%
2: 31.7%
3: 28.5%
4: 9.2%
1: 39.6%
2: 31.3%
3: 24.0%
4: 5.2%
1: 29.5%
2: 37.8%
3: 25.7%
4: 7.1%
1: 39.8%
2: 29.5%
3: 25.0%
4: 5.7%
χ2= 25.5, 0.04
Percent with CES-D ≥ 2314.0 23.8%11.7% 11.5%11.6%15.9%χ2= 6.7, 0.24
CD4 count1061(474)1204 (603)531 (273)454 (264)423 (272)425(288)3 v 5*, 6!!
CD4 nadir771 (283)809 (394)301 (187)259 (195)183 (159)195 (145)3 v 5*, 6*
4 v 5!!
Months on HAART0 (0)0 (0)53.6 (35.6)58.0 (39.3)71.3 (33.4)64.2 (36.6)3 v 5*
4 v 5!
HCV RNA levels0.67 M
(0.28-3.46)
1.59 M
(0.65 M – 3.29 M)
1.91 M
(0.44–4.7 M)
All NS
HIV levels98
(< 80, 4400)
92
(< 80, 3200)
<80
(<80, 6500
260
(< 80, 4700)
All NS
FIB-40.64(0.69)1.79 (1.84)0.89 (0.58)2.76 (7.4)1.20 (0.93)2.20 (1.36)1 v 2!!, 3*, 5*, 6*
2 v 3!
3 v 5*, 6*
5 v 6*
APRI0.19 (0.18)0.73(0.95)0.28 (0.24)1.12(3.98)0.34 (0.28)0.72 (0.57)1 v 2!!, 3*, 5*, 6*
3 v 6*
5 v 6*
Percent Baseline intravenous drug users10.5%78.6%9.2%82.3%18.3%89.8%χ2 = 559, p <.001
Percent using Heroin in past 6 months2%14%1%2%2%10%χ2 = 45.9, <0.001
Percent using cocaine in last 6 months9.4%23.8%4.6%13.7%7.5%19.3% χ2= 38.3, <0.001
Percent reporting >14 drinks/wk6.7%9.5%2.3%5.3%4.6% 11.6%χ2= 19.1, 0.002
Stroop124 (30)139 (36)126 (34)141 (40)137 (37)144 (47)1 v 4!!, 5*, 6!!
3 v 4!!, 5!!, 6!!
SDMT45.2 (11.8)37.8 (10.3)43.3 (12.6)39.5 (11.6)42.0 (12.1)36.4 (12.2)1 v2!!, 4*, 5!!, 6*
2 v 3!!
3 v 6*
5 v 6!!
Trails A36.0 (13.8)43.1 (18.0)39.2 (16.6)43.8 (21.7)39.1 (23.5)44.8 (22.1)1 v 3!!, 4!!, 6!!
Trails B
85.1 (41.5)128.9 (77.6)89.8 (43.8)104.3 (59.0)95.6 (56.6)114.1 (60.9)1 v 2!!, 4!, 6!!
2 v 3!
3 v 6!!
*<0.001,
!0.01 ≤ p <0.05,
!!0.001 ≤ p < 0.01.

SDMT – symbol digit (modalities) test. See methods for description of education levels.